Neurogene 주식 가격. NGNE - 주식 시세, 차트, 과거 거래, 주식 채팅, 재무.

실시간 스트리밍 인용문, 아이디어 및 실시간 토론을 위한 허브

프리미엄

가격

15.72

매수가

15.51

매도가

15.60

거래량

226,529

14.44 일간 변동폭 16.15

12.49 52주 범위 74.49

market_cap

204.26M

전일 종가

15.33

개장가

15.06

최근 거래 시간

15.52

마지막 거래 시간

04:03:17

재정 규모

US$ 3,508,186

VWAP

15.4867

평균 볼륨(3m)

257,281

발행 주식

12,993,613

배당수익률

주가수익률

-5.61

주당순이익(EPS)

-2.8

매출

순이익

-36.32M

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional ge... Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York. 더 보기

섹터

Pharmaceutical Preparations

산업

Pharmaceutical Preparations

웹사이트

www.neoleukin.com

본부

Wilmington, Delaware, USA

설립됨

Neurogene Inc is listed in the Pharmaceutical Preparations sector of the 나스닥 with ticker NGNE. The last closing price for Neurogene was US$15.33. Over the last year, Neurogene shares have traded in a share price range of US$ 12.49 to US$ 74.49.

Neurogene currently has 12,993,613 shares in issue. The market capitalisation of Neurogene is US$199.19 million. Neurogene has a price to earnings ratio (PE ratio) of -5.61.

Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates

Announced positive interim clinical data with 1E15 vg dose of NGN-401 gene therapy trial for Rett syndrome Neurogene to advance NGN-401 at 1E15 vg dose Expects to provide an update on...

Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced an update...

Neurogene Reports Positive Interim Efficacy Data from First Four Low-Dose Pediatric Participants in NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

All participants experienced a 2-point improvement in the clinician-rated Clinical Global Impression-Improvement (CGI-I) scale from baseline All participants improved in the caregiver-completed...

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	-26.123161	-62.431136596	41.843161	43.24	14.44	1007748	22.08339912	CS
4	-32.97	-67.7141096734	48.69	74.49	14.44	531552	38.01832273	CS
12	-20.19	-56.223893066	35.91	74.49	14.44	257281	39.78398178	CS
26	-18.31	-53.8054657655	34.03	74.49	14.44	185405	38.978162	CS
52	1.15	7.89293067948	14.57	74.49	12.49	153490	37.94078758	CS
156	1.15	7.89293067948	14.57	74.49	12.49	153490	37.94078758	CS
260	1.15	7.89293067948	14.57	74.49	12.49	153490	37.94078758	CS

가장 활성
% 상승자
% 패자

기호	가격	볼륨
CRNCCerence Inc	US$ 6.12 (117.02%)	58.72M
WORXSCWorx Corporation	US$ 1.9761 (101.64%)	128.75M
SPAISafe Pro Group Inc	US$ 4.54 (41.88%)	41.2M
ARQQArqit Quantum Inc	US$ 10.205 (39.03%)	586.64k
AOSLAlpha and Omega Semiconductor Limited	US$ 40.6859 (33.88%)	1.07M
SKKSKK Holdings Limited	US$ 1.07 (-76.54%)	18.62M
TMTCTMT Acquisition Corporation	US$ 2.54 (-60.56%)	253.35k
WCTWellchange Holdings Company Limited	US$ 1.31 (-60.54%)	1.53M
TMTCUTMT Acquisition Corporation	US$ 3.20 (-52.10%)	11.54k
GLXGGalaxy Payroll Group Ltd	US$ 2.10 (-46.29%)	2.05M
CDTConduit Pharmaceuticals Inc	US$ 0.1127 (22.10%)	547.79M
NVDANVIDIA Corporation	US$ 147.2388 (0.92%)	296.55M
ELABElevai Labs Inc	US$ 0.0206 (-3.74%)	200.9M
AKTSAkoustis Technologies Inc	US$ 0.1023 (17.45%)	197.53M
WORXSCWorx Corporation	US$ 1.9761 (101.64%)	128.75M